Trastuzumab coats HER2+ cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells) to induce antibody‑dependent cellular cytotoxicity (ADCC), leading to lysis of the target cells; signaling blockade contributes but ADCC is the primary killing mechanism.